Vyome Holdings, Inc
Close on Oct 19, 2026
- Market cap
- $12.91M
- P/E (TTM)
- –
- Dividend yield
- –
About Vyome
Pharmaceutical Preparations, SIC 2834
Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for immuno-inflammatory and rare diseases with significant unmet needs. Operating through biotechnology and pharmaceutical segments, the company primarily develops repurposed molecules for orphan conditions. Its biotechnology pipeline includes VT-1953, a topical gel being evaluated for treating symptoms of malodorous malignant fungating wounds in advanced cancer patients, and VT-1908, an ophthalmic drop program under development for steroid-sparing anterior uveitis. Through its pharmaceutical segment, the company develops topical antifungal products utilizing its Molecular Replacement Therapeutics platform, which are licensed to commercial partners for target patient populations.
The company operates across the United States and India, leveraging a dual-country development model for clinical recruitment and operational activities. Commercialized antifungal products are distributed in India under licensing agreements with Sun Pharma Laboratories Limited. Vyome Holdings maintains executive offices in Cambridge, Massachusetts, and conducts operations across Princeton, New Jersey, and New Delhi, India.
Summary of the business section of Vyome's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vyome Holdings, Inc
- Founded
- 2017
- Headquarters
- San Clemente, CA
- Address
- 1001 Calle Amanecer 92673
- Phone
- (949) 429-6680
- Employees
- 18, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Kreit and Chiu CPA LLP, Los Angeles, California
Stock & identifiers
- Ticker
- HIND
- Exchange
- Nasdaq
- IPO date
- Oct 6, 2016
- Shares outstanding
- 7M, Aug 12, 2026
- Public float
- $6.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-201 reverse, Mar 18, 2026; 1-for-4 reverse, Aug 15, 2025; 1-for-25 reverse, May 9, 2025; 1-for-58 reverse, Sep 23, 2024; 1-for-58 reverse, Sep 23, 2024; 1-for-50 reverse, Dec 23, 2022; 1-for-50 reverse, Dec 23, 2022; 1-for-10 reverse, Jul 25, 2019; 1-for-10 reverse, Jul 24, 2019
- SEC CIK
- 1427570
- CUSIP
- 92943X104
- ISIN
- US92943X1046
- LEI
- 549300TKI48OFOSV4780
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Venkateswarlu Nelabhotla | President and CEO, Director | 7 |
| Jerry Leonard | Chief Financial Officer | – |
| Robert Dickey IV | Chief Financial Officer | 762 |
| Mohanjit Jolly | Director | 454,456 |
| Stanley D. Pomichter III | Director | – |
| Shiladitya Sengupta | Director | – |
| John M. Tincoff III | Director | – |
Employees
Headcount reported in annual reports
“had 18 employees/retainers, of which 9 were full-time and 9 were part-time.”
Corporate history
Events identified from SEC filings